Application of Botulinum Neurotoxin in Lower Urinary Tract Dysfunctions: Where Are We Now?

© 2022 by the authors; CC BY-NC-ND license

adverse events; lower-urinary-tract dysfunction; therapeutic efficacy; urinary incontinence; voiding dysfunction; botulinum toxin A; onabotulinum toxin A; bladder pain syndrome/interstitial cystitis; long-term treatment; bladder pain syndrome; botulinum toxin A; interstitial cystitis; Sapylin; botulinum toxin A; liposome; bladder oversensitivity; interstitial cystitis; detrusor overactivity; interstitial cystitis/bladder pain syndrome; botulinum toxin A injection; urine biomarkers; bladder inflammation; botulinum toxin; urethral; voiding dysfunction; detrusor underactivity; urethral sphincter dysfunction; voiding dysfunction; detrusor underactivity; dysfunctional voiding; poor relaxation of the external sphincter; onabotulinum toxin A; botulinum toxins; type A; urinary bladder; overactive; aged; postoperative complications; spinal cord injury; neurogenic bladder; onabotulinumtoxinA; botox; platelet-rich plasma; interstitial cystitis; intravesical injection; botulinum toxin A; incontinence; Parkinson’s disease; stroke; dyssynergia; botulinum toxin; overactive bladder; men; spinal cord injury; botulinum toxins; lower urinary tract symptoms; n/a